Term
VTE PPX options:
-mechanically blocks thrombi from causing PE
-Wont prevent DVT or postthrombotic syndrome
-useful if anticoag is contraindicated
-large venous collateral vessels can dev. |
|
Definition
|
|
Term
VTE PPX options:
prevention of choice
5,000 units SC q8-12hrs |
|
Definition
|
|
Term
VTE PPX options:
maintain aPTT w/in therapeutic range at midpt of dosing interval |
|
Definition
|
|
Term
VTE PPX options:
approved for hip & knee replacement |
|
Definition
| Enoxaparin-Lovenox 30mg Sc q12h |
|
|
Term
VTE PPX options:
approved for Hip replacement, abdominal sugery, & gen medical PPX |
|
Definition
| Enoxaprin (Lovenox)-40mg SC qd |
|
|
Term
VTE PPX:
2500 IU SC pre-op and post-op, then 5000 IU SC qd
5000 IU SC qd beginning day before surgery |
|
Definition
|
|
Term
VTE PPX options:
approved for VTE PPX after abdominal & hip sugery |
|
Definition
|
|
Term
VTE PPX options:
approved for DVT PPX for hip & knee replacement & hip fracture surgery |
|
Definition
| Fondaparinex-Arixtra 2.5mg SC q6-8h after abdominal sugery, then q24h |
|
|
Term
VTE PPX options:
dosed to maintain an INR in the range of 2.0-3.0 |
|
Definition
|
|
Term
VTE PPX options:
10mg qd w/out regard to meals beginning at least 6-10hrs after sugery
|
|
Definition
|
|
Term
VTE PPX options:
treat THR:35 days
treat TKR:12 days |
|
Definition
|
|
Term
| fondaparinux 2.5mg 6-24h after sugery, then qd |
|
Definition
|
|
Term
| fondaparinux 2.5mg 6-8h after sugery, then qd |
|
Definition
|
|
Term
| INR> therapeutic but<4.5 w/ no blding |
|
Definition
lower dose or omit a dose
resume therapy at appropriate dose when INR is therapeutic
if INR only minimally greater than therapeutic, no dose reduction may be required |
|
|
Term
| INR≥4.5 but < 10, no sig blding |
|
Definition
omit 1-2 doses
monitor INR more freq, and resume therapy at an approp dose when INR therapeutic |
|
|
Term
| INR>10 w/ no evidence of blding |
|
Definition
omit dose
oral vit k 5mg
indiv treatment approach |
|
|
Term
| serious blding risk at any elevated INR |
|
Definition
omit warfarin dose
4 factor prothrombin complex concentrate
vit K 10mg IV slow infusion/20min(q12h prn persistent INR elevation)
fresh frozen plasma
recomb factor VIIa |
|
|
Term
| Phytonadione (Vit K) for INr reversal- Oral |
|
Definition
preferrred when no active blding
1.4 day av for INR 6-10 to decline <4
ava as 5mg tab |
|
|
Term
|
Definition
gold std for hypertensive encephalopathy
|
|
|
Term
|
Definition
arterial and venous dilator
lowers BP w/in 1-2 min
doesnt apear to signif compromise CBF |
|
|
Term
|
Definition
↓ preload, afterload, and myocardial oxygen demand
↑ pulmonary shunting "coronary steal"
onset: w/in sec t1/2: 1-2 min |
|
|
Term
|
Definition
| 0.25 mcg/kg/min~10 mcg/kg/min |
|
|
Term
|
Definition
| treatment of choice for coronary ischemia |
|
|
Term
|
Definition
| used for: most indications, postop HTN, HTN w/ inc intercranial press |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| most indications, postop HTN, HTN w/ increase intrscranial press |
|
|
Term
|
Definition
| overshoot has offset & phelbitis |
|
|
Term
| 3rd gen CCB, ultrashort selective arteriolar vasodilator |
|
Definition
|
|
Term
|
Definition
| allergy to eggs/soy & hypertriglyceridemia |
|
|
Term
| selective Beta1 adren R antagonist |
|
Definition
|
|
Term
|
Definition
| aortic dissection and periop HTN and to control certain supraventricular arrythmias |
|
|
Term
|
Definition
| heart block, HF, asthma, hypotension |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| selec alpha1 and nonselc Beta R antagonist |
|
Definition
|
|
Term
|
Definition
DOC for
stroke/aortic dissection does not reduce CBF
excess catecholamine, such as pheochromocytoma or clonidine w/drawal
prego |
|
|
Term
| labetalol is second line for: |
|
Definition
|
|
Term
|
Definition
unpred dose reponse
may worsen CHF
in pheochromocytoma may induce paradoxical rise in BP |
|
|
Term
|
Definition
| scalp tingling, bronchocontriction heart block |
|
|
Term
| active metabolites (post-drug) of enalapril |
|
Definition
|
|
Term
|
Definition
| for prevention or management of postop HTN pt perviously treated w/ ACEI |
|
|
Term
|
Definition
precipitous fall in BP in high renin states
variable response
NOT DOC AMI or renal failure |
|
|
Term
| direct vasodilating agent (arterioles) |
|
Definition
|
|
